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ORIGINAL ARTICLE
Axillary lymph node (LN) involvement is the most
important independent prognostic factor for
breast cancer.1,2 Postoperative adjuvant systemic
therapy is regularly indicated for patients with pos-
itive axillary LN metastasis.3 Until recently, axillary
LN dissection (ALND) has been the standard
surgical procedure to determine the axillary LN
staging for this type of patient. However, early
and long-term complications such as seroma 
formation, sensory changes, lymphedema and
chronic pain, have been observed frequently in
the ipsilateral arm of patients with ALND.
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Background/Purpose: Sentinel lymph node (LN) biopsy has been widely adopted in the axillary staging
of clinical node-negative breast cancer patients. This study aimed to evaluate the accuracy of radio-guided
sentinel LN (SLN) biopsy (SLNB) using the periareolar injection technique for predicting the histopatho-
logic status of axillary LNs in early breast cancer patients.
Methods: Between November 2003 and November 2004 in the National Taiwan University Hospital,
radio-guided SLNB using the periareolar injection technique was consecutively performed in 213 female
patients with early breast cancer (stage T1 and T2) but without clinically palpable axillary LN and previous
chemotherapy. Two mCi of filtered (0.22 μm) 99mTc-sulfur colloid were injected in the afternoon 1 day 
before surgery (2-day protocol) or 1 mCi of the same radiopharmaceutical was injected on the morning of
the surgery (1-day protocol). During surgery, a handheld gamma probe was used to identify the LNs with
radioactivity in the axilla. A node was deemed a SLN if its radioactivity was > 10% of the hottest node. All
the SLNs identified were removed for histology.
Results: Radioactive SLN was identified at surgery in 207 patients. The SLN identification rate was 97.2%
(207/213). Of these 207 patients, 163 patients had received both SLNB and axillary LN dissection. Among
these 163 patients, 77 patients had LN metastases and four had negative SLN but positive non-SLN. The
false-negative rate of SLNB for the detection of axillary LN metastases was 5.2% (4/77). There were no sta-
tistical differences between false-negative and SLN positive groups for all factors.
Conclusion: Our study suggests that SLNB with periareolar injection of radiocolloid provides valuable 
information on the axillary nodal status in patients with early breast cancer. [J Formos Med Assoc 2007;
106(1):44–50]
Key Words: breast cancer, periareolar injection, sentinel lymph node biopsy, 99mTc radiocolloid
©2007 Elsevier & Formosan Medical Association
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Departments of 1Nuclear Medicine, 2Surgery, 3Pathology and 5Laboratory Medicine, National Taiwan University Hospital and National
Taiwan University College of Medicine, and 4Institute of Preventive Medicine, National Taiwan University College of Public Health,
Taipei, Taiwan.
Received: October 12, 2005
Revised: November 28, 2005
Accepted: June 6, 2006
*Correspondence to: Dr Chiun-Sheng Huang, Department of Surgery, National Taiwan University Hospital,
7 Chung-Shan South Road, Taipei 100, Taiwan.
E-mail: cshuang@ha.mc.ntu.edu.tw
Lately, sentinel LN biopsy (SLNB) has been
widely adopted in the axillary staging for clinical
node-negative breast cancer patients.4−8 Sentinel
LN (SLN) is defined as the first LN on the direct
lymphatic pathway draining from a tumor.9,10 It
has been generally accepted that the status of the
SLN is able to accurately predict the histopatho-
logic status of the regional lymphatic basin.11 If
the SLN is free of tumor metastasis, it is usually
expected that the tumor will not spread to the at-
risk regional lymphatic basin and ALND for the
patient is unnecessary.5
There are various techniques for SLN identifi-
cation and localization. They vary according to the
material used, such as blue dye or radioisotope-
labeled colloid,12−17 and according to the site of
injection, such as peritumoral, subdermal18−20 or
sub/periareolar.21−25 The objective of this study
was to evaluate the accuracy of radio-guided SLNB
using the periareolar injection technique for pre-
dicting the histopathologic status of axillary LN
in early breast cancer patients in our hospital.
Patients and Methods
Patients
Between November 2003 and November 2004 in
the National Taiwan University Hospital, radio-
guided SLNB using the periareolar technique was
performed in 213 consecutive female patients
(mean age, 50.3 ± 11.1 years; range, 24–83 years)
with early breast cancer (stage T1 and T2; mean
tumor size, 2.4 ± 1.2 cm) and clinically non-
palpable axillary LN, and without previous chemo-
therapy. Preoperative diagnoses of breast cancer
for these 213 patients were established on either
cytology of fine-needle aspiration or histology 
of core or excisional biopsy specimens. Informed
consent was obtained from each patient.
Lymphoscintigraphy
Each patient had intradermal periareolar injection
in the quadrant where the tumor was located.
Two mCi of filtered (0.22 μm) 99mTc-sulfur col-
loid were injected in the afternoon 1 day before
surgery (2-day protocol) or 1 mCi of the same ra-
diopharmaceutical was injected on the morning
of surgery (1-day protocol).
Images were acquired using large-field-of-view
gamma cameras equipped with low energy high
resolution collimators. Imaging was performed
in anterior projection or both anterior and lateral
projections while the patient’s arm extended to-
ward the head for maximal axillary exposure. To
improve on anatomic detail, a cobalt 57 flood
source was placed behind the patient for a trans-
mission scan. The images were taken every 30 min-
utes until tracer activity could be identified in the
axillary regions. The skin directly over the SLN(s)
was then marked with a surgical skin marker to
locate the SLN(s) during surgery.
SLNB
During surgery, a handheld gamma probe (Navi-
gator GPS; US Surgical Corp., Tyco Healthcare
Group, Norwalk, CT, USA) was used to identify
the LNs with radioactivity in the axilla. A node was
deemed to be a SLN if its radioactivity was >10%
of the hottest node. All the SLNs identified were
then removed for histology. The biopsy sites were
re-examined after harvesting the SLNs to ensure
that all radioactive LNs had been removed. A
routine level I and II ALND was subsequently
performed after SLNB in 163 patients.
Pathologic evaluation
A series of sections for each LN embedded in a
paraffin block were examined using hematoxylin
and eosin as well as immunohistochemical stain-
ing with anti-cytokeratin antibodies.
Statistical analysis
All data are expressed as mean ± standard devi-
ation. Comparisons between different groups were
performed using two-tailed paired and unpaired
Student’s t tests. Statistical analyses were per-
formed using SAS version 8.1 (SAS Institute, Cary,
NC, USA) for Windows. Logistic regression was
used to evaluate the relative risk between two
groups. The sentinel node identification rate was
defined as the ratio of the number of patients
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with detected SLN over the total number of pa-
tients that were injected with 99mTc-sulfur colloid.
The axillary metastatic rate was calculated by di-
viding the number of patients with axillary metas-
tasis by the number of patients enrolled in the
study. Patients with negative sentinel node but
with positive axillary metastases in one or more
of the non-sentinel LNs (NSLNs) were identified
as having a false-negative result. The false-negative
rate was defined as the number of false-negative  
patients divided by the total number of patients
with metastases in either SLN or NSLN.
Results
Patients
A total of 213 patients received intradermal peri-
areolar injections of filtered 99mTc-sulfur colloid.
Radioactive SLNs were not identified at surgery
in six of the 213 patients who received SLNB. The
SLN identification rate in this study was there-
fore 97.2% (207/213). The patients’ characteris-
tics are shown in Table 1. The mean age of the 
six patients with failed SLNB was slightly higher
than that of the 207 patients with successful
SLNB (58.3 ± 22.5 vs. 50.1 ± 10.6), but the differ-
ence was not statistically significant (p = 0.4159).
For these six patients, 50% (3 patients) had 
received excisional biopsies before SLNB, 33%
(2 patients) were later discovered to have axillary
LN metastases by ALND and 50% (3 patients)
underwent the 1-day protocol. There were no statis-
tically significant differences between “successful
SLNB” and “failed SLNB” patients for all factors
including previous excisional biopsies, positive
axillary metastases and 1-day protocol.
Of the 207 patient whose SLNs were identi-
fied successfully, 44 had elected SLNB and not to
undergo ALND because of negative SLN.
Pathologic results for patients who 
received both SLNB and ALND
The remaining 163 patients, who underwent both
SLNB and ALND successfully, were included in the
data analysis. The accuracy of SLNB was examined
by comparing the histopathology of SLN and
NSLN. Table 2 summarizes the results. There were
73 patients with SLN metastases; the SLN metasta-
tic rate was 44.8% (73/163). There were 77 pa-
tients with LN metastases in SLN, axillary NSLN,
or both; the axillary metastatic rate was 47.2%
(77/163). Forty-four patients (57.1%) had posi-
tive SLN but no tumor involvement of NSLN,
Table 1. Profiles of the 207 patients with successful sentinel lymph node biopsy (SLNB) and six patients 
with failed SLNB*
Successful SLNB Failed SLNB p
Number of patients 207 6 –
Age (yr) 50.1 ± 10.6 58.3 ± 22.5 0.4159
Primary tumor size (cm) 2.3 ± 1.2 2.8 ± 1.7 0.3944
Previous excisional biopsy 47 (23) 3 (50) 0.1199
Positive axillary basins 77 (37) 2 (33) 0.8568
1-day protocol 78 (38) 3 (50) 0.5400
*Data are presented as mean ± standard deviation or n (%).
Table 2. Pathologic lymph node results for the 
163 patients who received both sentinel
lymph node biopsy and axillary lymph
node dissection
Final pathology 
(including SLN and NSLN)
Positive Negative Total
SLN
Positive 73 0 73
Negative 4 86 90
Total 77 86 163
SLN = sentinel lymph node; NSLN = non-sentinel axillary lymph
node.
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and four patients had negative SLN but posi-
tive tumor involvement in NSLN. The sensitivity,
specificity, negative predictive value and false-
negative rate of SLNB for the detection of axillary
lymph node metastases were 94.8% (73/77),
100% (86/86), 95.6% (86/90) and 5.2% (4/77),
respectively.
The patients’ characteristics, which include age,
primary tumor size, number of SLN examined,
number of NSLN examined, cases with previous
excisional biopsy, and cases with 1-day protocol,
are presented in Table 3 under the “false-negative”
and “SLN-positive” columns. There were no sta-
tistical differences between these two columns for
all factors corresponding to rows in Table 3.
Among the 73 patients whose SLNs were
identified as positive for metastasis, 62 showed
positive results for their hottest SLN; seven pa-
tients were found to have negative results for
their hottest SLN but positive results for their
second hottest SLN; four patients were found to
have positive results beginning from their third
hottest SLN.
Comparison between 1-day and 2-day
protocols
The comparison between 1-day and 2-day proto-
cols is illustrated in Table 4. Sixty-four patients
underwent SLNB using the 1-day protocol and
the remaining 99 patients adopted the 2-day
protocol for their SLNB. The two groups differed
significantly in the age category (47.5 ± 9.1 vs.
52.4 ± 11.3; p = 0.0041), but not in the categories
of the number of SLN examined, the number of
cases with LN metastases and false-negative rates.
The 1-day protocol was usually adopted for after-
noon surgery while the 2-day protocol was adopted
for morning surgery. In our hospital, the elderly
patients were, by courtesy, usually scheduled for
surgery in the early morning. Therefore, the mean
Table 3. Profiles of the four patients with false-negative sentinel lymph node (SLN) and 73 patients with
positive SLN*
False-negative Positive SLN p
Number of patients 4 73 –
Age (yr) 50.0 ± 5.2 50.6 ± 11.0 0.9215
Primary tumor size (cm) 2.8 ± 0.9 2.5 ± 1.2 0.5675
Number of SLN examined 2.0 ± 0.8 3.4 ± 2.5 0.2828
Number of NSLN examined 14.5 ± 8.4 12.8 ± 7.0 0.6513
Cases with previous excisional biopsy 0 (0) 11 (15) –
Cases with 1-day protocol 2 (50) 23 (32) 0.2595
*Data are presented as mean ± standard deviation or n (%). NSLN = non-sentinel axillary lymph node.
Table 4. Comparison between 1-day and 2-day protocols*
1-day protocol 2-day protocol p
Number of patients 64 99 –
Age (yr) 47.5 ± 9.1 52.4 ± 11.3 0.0041†
Tumor size (cm) 2.4 ± 1.4 2.5 ± 1.2 0.7816
Number of SLN examined 3.8 ± 2.3 3.2 ± 2.4 0.1118
Number of NSLN examined 13.0 ± 7.6 11.9 ± 7.5 0.3688
Cases with LN metastases 26 (41) 51 (52) 0.1738
Number of false-negative cases 2 2 –
False-negative rate (%) 7.6 4.0 0.5999
*Data are presented as mean ± standard deviation or n (%); †p < 0.05. SLN = sentinel lymph node; NSLN = non-sentinel axillary lymph
node; LN = lymph node.
age of patients in the 2-day protocol group was
higher than that of the 1-day protocol group.
Lymphoscintigraphy
Lymphoscintigraphy was performed for all patients
using the intradermal periareolar injection tech-
nique. Clear focal accumulation of radioactivity
was visible at the ipsilateral axilla in 206 of 213
lymphoscintigraphic images (96.7%); three of
these 206 patients failed SLNB. Among the seven
patients whose lymphoscintigraphy failed to reveal
obvious nodal uptake in the ipsilateral axilla, four
were identified to have radioactive SLN at surgery
using more sensitive handheld probes. Internal
mammary (IM) drainage was noted in two patients
of the total 213 patients under study; the IM 
visualization rate was 0.9% (2/213).
Discussion
Since its introduction in the mid 1990s, SLNB has
been widely adopted for axillary staging in patients
with early breast cancer. Although numerous SLNB
techniques that vary on the choice of localizing
agent(s), the particle size of the agent, timing of
injection, and site of injection have been utilized,
a recent meta-analysis found that the results of
SLNB do not vary significantly among these differ-
ent techniques and are generally in agreement with
results from ALND.26 The pattern of lymphatic
drainage of the breast is unique. It travels cen-
tripetally to the subareolar plexus and then to
the axilla via lymphatic collecting channels. This
was first described by Sappey and affirmed by
many studies thereafter.27 It has now been widely
accepted that tumors of the breast, regardless of
location, drain through a common afferent lym-
phatic channel to a common axillary SLN. This is
likely to be the reason that the same SLN is iden-
tified by peritumoral or periareolar injection of
blue dye or radiocolloid.28−32
The periareolar injection technique has sev-
eral advantages over other techniques.
1. It does not require accurate injection site and
is relatively easy to perform.
2. Since the tracers are efficiently and rapidly
taken up by the dense subareolar plexus, SLN
is more rapidly visualized in the axilla.25 As
the percentage of tracer reaching the SLN is
higher when injected via the periareolar route
than via the subdermal/peritumor route, it is
easier to identify SLN by periareolar injection
than by subdermal/peritumor injection.
3. For patients with non-palpable tumor, the 
periareolar approach dispenses with image-
guided injection.28
4. It is possible to perform SLNB in patients
with multicentric tumors using the periareo-
lar injection technique.33−34
5. For a tumor located in the outer upper quad-
rant of the breast, periareolar injection, which
increases the distance between the injection
site and axillary SLN, reduces the shine-through
effect.7
In view of the above advantages, we have
adopted periareolar injection of radiolabeled
tracer to localize SLN in our hospital. It has been
reported that IM SLN could not be identified by
periareolar injection.35 In this study, only two IM
drainages were noted out of the total of 213 cases.
Although IM SLNB is feasible, patients with posi-
tive IM nodes but negative axillary nodes are rare.
The impact of determining IM LN status on patient
management, disease-free and overall survival has
not yet been established.36 At present, IM SLNB is
not routinely performed in our hospital.
The SLN identification rate in this study was
97.2% (207/213), and the false-negative rate was
5.2%. Although Schrenk et al reported that the
accuracy of SLNB did not increase with more SLN
removals,36 our study nevertheless shows that the
number of false-negative cases would be increased
to eight (10.4%) if we only excised the first two
hottest SLNs for the 77 positive SLN patients in
our study. This is in agreement with the suggestion
in previous studies to completely excise all radio-
active SLNs to reduce the false-negative rate.13,16
Previous studies suggest that the optimal inter-
val between injection and SLNB is from 30 minutes
to 24 hours.7,8,37−40 Recently, Chua et al proposed
that the optimal interval between injection and
R.F. Yen, et al
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surgery is in the range of 20–300 minutes.41 Our
results show no difference in the number of SLNs
harvested and the false-negative rates between
patients under the 1-day protocol (interval of
1–6 hours) and patients under the 2-day protocol
(interval of 16–20 hours). The 2-day protocol has
the advantages of high SLN-to-background and
significantly low radioactivity in the resected
specimen relative to the 1-day protocol.42,43
Conclusion
Our study suggests that SLNB with periareolar in-
jection of radiocolloid and gamma probe-guided
technique is a simple and effective procedure for
SLN sampling in patients with early breast can-
cer. The SLNB result provides accurate and useful
information on the status of axillary nodes.
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